// App-Quantinova.ai

2834 : Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Fotini Vogiatzi

Principal Investigators

  • Kristina Mller

  • Dorothee Winterberg

  • Thies Rsner

  • Lennart Lenk

  • Gunnar Cario

  • Martin Schrappe

  • Andreas E. Kulozik

  • Beat Bornhauser

  • Jean-Pierre Bourquin

  • Thomas Valerius

  • Matthias Peipp

  • Christian Kellner

  • Denis Martin Schewe

Medical Centers

  • Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian-Albrechts-University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany, Kiel, Germany

  • Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian-Albrechts-University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany, Kiel, Germany

  • Division of Stem Cell Transplantation and Immunotherapy, nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany

  • UKSH Kiel, Kiel, Schleswig Holstein, Germany

  • Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian-Albrechts-University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany, Kiel, Germany

  • Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg and Hopp Children’s Cancer Center at Nationales Centrum for diseases Heidelberg, Heidelberg, Germany, Heidelberg, Germany

  • Division of Pediatric Oncology, and Children Research Center, University Children´s Hospital, Zurich, Switzerland, Zurich, Switzerland

  • Universitaets-Kinderspital Zurich, Zurich, Switzerland

  • Division of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, LMU Munich, Munich, Germany, Munich, Germany

  • Pediatric Hematology/Oncology, Kiel, Germany

Locations

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • T-cell acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 163

  • Cluster of Differentiation 38

  • Cluster of Differentiation 47

  • Colony stimulating factor 1

Drug/Treatment

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved